CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...